Keyword: Rare Pediatric Disease Priority Review Boucher (PPRV)
News
21.08.2015
- US biotechnology company United Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Boucher (PPRV) to a subsidiary of biopharmaceutical firm AbbVie for $350...